Heel pain management with Agnikarma
Phase 2
- Conditions
- Health Condition 1: M722- Plantar fascial fibromatosis
- Registration Number
- CTRI/2019/04/018369
- Lead Sponsor
- Dr S P Badole
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age:-20 to 60 years
2. Gender:-Both
3. Patients with classical signs and symptoms of plantar fasciitis and giving voluntary informed consent.
Exclusion Criteria
1.Uncontrolled Diabetes(HbA1c > 7.5) and with its complication
2.Pregnancy and lactation
3. Infective foot pathology
4. Fracture
5. Rheumatism, Gout
6. Nerve entrapment syndromes
7. sciatica
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain <br/ ><br> <br/ ><br>Timepoint: Day 4,8,12,16,30,60,90
- Secondary Outcome Measures
Name Time Method Agnikarma with Mrutika Shalaka relives pain of plantar fasciitis instantly <br/ ><br> <br/ ><br> <br/ ><br>Secondary OutcomeAgnikarma with Mrutika Shalaka reduces thickness of plantar fascia in the plantar fasciitis and is significantly more effective than the standard modality of Therapeutic Ultrasound <br/ ><br> <br/ ><br>Timepoint: Day 4,8,12,16,30,60,90
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Agnikarma's efficacy in plantar fascial fibromatosis (M722)?
How does Agnikarma with Mrutika Shalaka compare to therapeutic ultrasound for M722 treatment outcomes?
What biomarkers predict response to Agnikarma in CTRI/2019/04/018369 plantar fasciitis trial?
Are there adverse events reported in Agnikarma trials for heel pain management?
How does Agnikarma integrate with corticosteroid injections for plantar fasciitis management?